This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

FDA expands pediatric indication for Rinvoq

FDA expands pediatric indication for rinvoq

The U.S. Food and Drug Administration has expanded indications for AbbVie's Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA).

Rinvoq is indicated for with an inadequate response or intolerance to one or more (TNF) blockers. In addition, Rinvoq LQ, a new weight-based oral solution, is available for these pediatric patients.

The expanded indication is based on pharmacokinetic data from 51 patients with pJIA with active polyarthritis and safety data from 83 patients with pJIA with active polyarthritis. At the recommended doses, upadacitinib plasma exposures in pediatric patients with pJIA and PsA are expected to be comparable to those observed in adults with rheumatoid arthritis and PsA based on population pharmacokinetic modeling and simulation.

"Pediatric patients with pJIA and PsA can be severely limited in their ability to complete daily physical tasks and participate in everyday activities. Understanding their needs today and knowing the likelihood of disease in adulthood underscores the need for additional treatment options," Aarat Patel, M.D., from the Bon Secours Rheumatology Center of St. Mary's Hospital in Richmond, Virginia, said in a statement.

"Having a available for patients who do not respond well to a TNF inhibitor addresses a need for the health care community, patients, and their families."

More information: More Information

Copyright © 2024 HealthDay. All rights reserved.

Citation: FDA expands pediatric indication for Rinvoq (2024, June 24) retrieved 17 July 2024 from https://medicalxpress.com/news/2024-06-fda-pediatric-indication-rinvoq.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA approves first pill to treat moderate-to-severe Crohn's disease

 shares

Feedback to editors